Inmune Bio Earnings Estimate

INMB
 Stock
  

USD 9.34  0.04  0.43%   

Many public companies, such as Inmune Bio, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Inmune Bio's earnings estimates, investors can diagnose different trends across Inmune Bio's analyst sentiment over time as well as compare current estimates against different timeframes.
Inmune Bio is projected to generate -1.91 in earnings per share on the 31st of December 2021. Inmune Bio earnings estimates module stress-tests analyst consensus about projected Inmune Bio EPS (Earning Per Share) to derive its highest and lowest estimates based on its historical volatility. Please see Risk vs Return Analysis.
  
As of August 10, 2022, Gross Profit is expected to decline to about 150.8 K

Inmune Bio Earnings Estimation Breakdown

Calculation of earning per share of Inmune Bio is based on official Zacks consensus of 1 analysts regarding Inmune Bio future annual earnings. Given the historical accuracy of 59.33%, the future earnings per share of Inmune Bio is estimated to be -1.91 with the lowest and highest values of -1.91 and -1.91, respectively. Please note that this consensus of annual earnings estimates for Inmune Bio is an estimate of EPS before non-recurring items and including employee stock options expenses
  Current EPS -1.59
-1.91
Lowest
Expected EPS -1.91
-1.91
Highest

Inmune Bio Earnings Projection Consensus

Suppose the current estimates of Inmune Bio's value are higher than the current market price of the Inmune Bio stock. In this case, investors may conclude that Inmune Bio is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Inmune Bio's stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyCurrent EPSEPS Estimate for 31st of December 2021

1

59.33%

-1.59

-1.91

Inmune Bio Earnings per Share Projection vs Actual

Actual Earning per Share of Inmune Bio refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Inmune Bio predict the company's earnings will be in the future. The higher the earnings per share of Inmune Bio, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Inmune Bio Estimated Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Inmune Bio, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Inmune Bio should always be considered in relation to other companies to make a more educated investment decision.

Inmune Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact Inmune Bio's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2022-08-03
2022-06-30-0.5-0.380.1224 
2022-05-05
2022-03-31-0.64-0.390.2539 
2022-03-03
2021-12-31-0.58-0.550.03
2021-11-03
2021-09-30-0.35-0.55-0.257 
2021-08-04
2021-06-30-0.34-0.44-0.129 
2021-05-05
2021-03-31-0.27-0.32-0.0518 
2021-03-04
2020-12-31-0.31-0.260.0516 
2020-11-05
2020-09-30-0.17-0.36-0.19111 
2020-08-05
2020-06-30-0.2-0.20
2020-05-14
2020-03-31-0.21-0.190.02
2020-03-11
2019-12-31-0.25-0.220.0312 
2019-11-08
2019-09-30-0.19-0.28-0.0947 
2019-08-09
2019-06-30-0.19-0.040.1578 
2019-05-15
2019-03-31-0.19-0.2-0.01
2019-03-29
2018-12-31-0.19-0.21-0.0210 

About Inmune Bio Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Inmune Bio earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Inmune Bio estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Inmune Bio fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for 2022
Accumulated Retained Earnings Deficit-63.7 M-65.4 M
Earning Before Interest and Taxes EBIT-30.3 M-31.1 M
Earnings per Basic Share(1.88) (1.93) 
Earnings per Diluted Share(1.88) (1.93) 
Price to Earnings Ratio(5.43) (5.86) 
Earnings Before Interest Taxes and Depreciation Amortization EBITDA-30.3 M-31.1 M
Earnings before Tax-30.3 M-31.1 M
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patients innate immune system to treat disease. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida. Inmune Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Inmune Bio without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Theme Ratings Now

   

Theme Ratings

Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Inmune Bio using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Risk vs Return Analysis. Note that the Inmune Bio information on this page should be used as a complementary analysis to other Inmune Bio's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.

Complementary Tools for Inmune Stock analysis

When running Inmune Bio price analysis, check to measure Inmune Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inmune Bio is operating at the current time. Most of Inmune Bio's value examination focuses on studying past and present price action to predict the probability of Inmune Bio's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Inmune Bio's price. Additionally, you may evaluate how the addition of Inmune Bio to your portfolios can decrease your overall portfolio volatility.
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Is Inmune Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inmune Bio. If investors know Inmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inmune Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
182.3 M
Quarterly Revenue Growth YOY
39.75
Return On Assets
-0.26
Return On Equity
-0.58
The market value of Inmune Bio is measured differently than its book value, which is the value of Inmune that is recorded on the company's balance sheet. Investors also form their own opinion of Inmune Bio's value that differs from its market value or its book value, called intrinsic value, which is Inmune Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inmune Bio's market value can be influenced by many factors that don't directly affect Inmune Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine Inmune Bio value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.